Fundamental Patent Broadens Protogene's Intellectual Property for Methods Of Creating Surface Tension Arrays

Apr 04, 2001, 01:00 ET from Protogene Laboratories, Inc.

    MENLO PARK, Calif., April 4 /PRNewswire/ -- Protogene Laboratories, Inc.
 today announced that the United States Patent and Trade Office has issued to
 the company patent number 6,210,894, entitled "Method and Apparatus for
 Conducting an Array of Chemical Reactions on a Support Surface."  This
 addition to Protogene's intellectual property portfolio broadly extends
 protection to methods of using functionalized microarrays for chemical
 reactions.  These methods include ink-jet deposition and spotting, where the
 individual array sites are separated by surface tension.  Issuance of this
 patent further solidifies Protogene's position as a technology leader in the
 development of high quality, custom microarrays that address the rapidly
 evolving needs of the life science research community.  The company's
 intellectual property portfolio covering its surface tension array technology
 dates back to 1991.
     This new patent, applicable to any type of array, includes claims to
 methods for conducting chemical reactions on an array surface, where the
 functionalized binding sites are separated using surface tension.  More
 specifically, the claims cover methods of making these arrays where the
 reaction sites are defined as a reactive hydrophilic site surrounded by a
 hydrophobic area, irrespective of the specific chemistry that creates the
 surface tension pattern.  The claims also cover methods of making spotted
 arrays of nucleic acids or other substances using arrays of functionalized
 binding sites created by differential surface tension.
     "We are delighted with the issuance of this patent, which extends
 Protogene's comprehensive worldwide protection for its intellectual property
 surrounding the use of surface tension to create arrays," said
 Christopher R. Wolf, President and CEO at Protogene.  "This fundamental patent
 provides the foundation for applying surface tension arrays to other
 applications including proteomics, drug binding assays, clinical diagnostic
 assays and combinatorial chemistries, among other applications."
     Protogene continues to move toward the commercialization of custom
 oligonucleotide DNA microarrays, manufactured through the unique combination
 of three technologies:  in situ synthesis of oligonucleotides, inkjet printing
 and patented surface tension array technology.  This combination of
 technologies enables Protogene to manufacture high quality oligonucleotide
 microarrays that are fully customizable to the particular needs of the
 individual researcher.  Oligonucleotide arrays generate more specific data
 than cDNA arrays, enabling scientists to perform more sophisticated and
 informative experiments required for the post-genome era.  The company's
 arrays are currently being tested at user sites for applications including
 genotyping and gene expression studies.
     Protogene Laboratories, Inc., based in Menlo Park, California, is a
 developer and marketer of high-quality, fully customizable microarrays for
 life sciences research.  Protogene's mission is to empower the individual
 researcher by making easy the rapid design and delivery of microarrays
 tailored to a user's own needs.  Protogene's microarrays are intended to be
 completely compatible with other leading genomics tools already found in the
 researcher's lab, thereby avoiding unnecessary capital expenditures and other
 restrictions to widespread access.  The privately held company was founded in
 November 1995 and currently has over 90 employees.  Information about
 Protogene is available on the Web at www.Protogene.com or by phoning
 Bob Barrett, vice president of sales and marketing, at 650-289-2970.
     Protogene Laboratories, Inc. cautions readers that forward-looking
 statements, including without limitations, those relating to the company's
 future business prospects are subject to certain risks and uncertainties that
 could cause actual results to differ materially from those indicated in the
 forward-looking statements, due to factors, such as those relating to
 economic, competitive, governmental, technological and other risks and
 factors.
 
 

SOURCE Protogene Laboratories, Inc.
    MENLO PARK, Calif., April 4 /PRNewswire/ -- Protogene Laboratories, Inc.
 today announced that the United States Patent and Trade Office has issued to
 the company patent number 6,210,894, entitled "Method and Apparatus for
 Conducting an Array of Chemical Reactions on a Support Surface."  This
 addition to Protogene's intellectual property portfolio broadly extends
 protection to methods of using functionalized microarrays for chemical
 reactions.  These methods include ink-jet deposition and spotting, where the
 individual array sites are separated by surface tension.  Issuance of this
 patent further solidifies Protogene's position as a technology leader in the
 development of high quality, custom microarrays that address the rapidly
 evolving needs of the life science research community.  The company's
 intellectual property portfolio covering its surface tension array technology
 dates back to 1991.
     This new patent, applicable to any type of array, includes claims to
 methods for conducting chemical reactions on an array surface, where the
 functionalized binding sites are separated using surface tension.  More
 specifically, the claims cover methods of making these arrays where the
 reaction sites are defined as a reactive hydrophilic site surrounded by a
 hydrophobic area, irrespective of the specific chemistry that creates the
 surface tension pattern.  The claims also cover methods of making spotted
 arrays of nucleic acids or other substances using arrays of functionalized
 binding sites created by differential surface tension.
     "We are delighted with the issuance of this patent, which extends
 Protogene's comprehensive worldwide protection for its intellectual property
 surrounding the use of surface tension to create arrays," said
 Christopher R. Wolf, President and CEO at Protogene.  "This fundamental patent
 provides the foundation for applying surface tension arrays to other
 applications including proteomics, drug binding assays, clinical diagnostic
 assays and combinatorial chemistries, among other applications."
     Protogene continues to move toward the commercialization of custom
 oligonucleotide DNA microarrays, manufactured through the unique combination
 of three technologies:  in situ synthesis of oligonucleotides, inkjet printing
 and patented surface tension array technology.  This combination of
 technologies enables Protogene to manufacture high quality oligonucleotide
 microarrays that are fully customizable to the particular needs of the
 individual researcher.  Oligonucleotide arrays generate more specific data
 than cDNA arrays, enabling scientists to perform more sophisticated and
 informative experiments required for the post-genome era.  The company's
 arrays are currently being tested at user sites for applications including
 genotyping and gene expression studies.
     Protogene Laboratories, Inc., based in Menlo Park, California, is a
 developer and marketer of high-quality, fully customizable microarrays for
 life sciences research.  Protogene's mission is to empower the individual
 researcher by making easy the rapid design and delivery of microarrays
 tailored to a user's own needs.  Protogene's microarrays are intended to be
 completely compatible with other leading genomics tools already found in the
 researcher's lab, thereby avoiding unnecessary capital expenditures and other
 restrictions to widespread access.  The privately held company was founded in
 November 1995 and currently has over 90 employees.  Information about
 Protogene is available on the Web at www.Protogene.com or by phoning
 Bob Barrett, vice president of sales and marketing, at 650-289-2970.
     Protogene Laboratories, Inc. cautions readers that forward-looking
 statements, including without limitations, those relating to the company's
 future business prospects are subject to certain risks and uncertainties that
 could cause actual results to differ materially from those indicated in the
 forward-looking statements, due to factors, such as those relating to
 economic, competitive, governmental, technological and other risks and
 factors.
 
 SOURCE  Protogene Laboratories, Inc.